Stem and progenitor cell harvesting, extracorporeal "graft engineering" and clinical use - Initial expansion vs current dillemas

Clinical Application of Immunology

Volumn 5, Issue 1, 2006, Pages 518-527

  Balint, Bela ^a,b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cryopreservation; Harvesting; Processing; Purging; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CITRIC ACID; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; BREAST CANCER; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; COMBINED IMMUNODEFICIENCY; CONGENITAL DISORDER; CRYOPRESERVATION; DRUG DOSE INCREASE; DRUG MEGADOSE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; ISOGRAFT; LIVER VENOOCCLUSIVE DISEASE; MONOTHERAPY; MULTIPOTENT STEM CELL; NEPHROBLASTOMA; NEUROBLASTOMA; OVARY CANCER; REVIEW; STEM CELL MOBILIZATION; TESTIS CANCER; THALASSEMIA; THROMBOCYTOPENIA; TOTIPOTENT STEM CELL;

EID: 34247280568     PISSN: 13120832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford: Blacwell Scientific Publications, 1997.
2. Brecher ME, editor. Technical Manual, 14th ed. Bethesda: AABB Press, 2002.
3. Balint B, Radovic M, Milenkovic Lj. Bone marow transplantation. Vojnosanit Pregl 1988; 45: 195-201.
4. Petakov M, Balint B. Bugarski D. Haematopoietic stem cell biology. In: Balint B, editor. Transfusion Medicine. Belgrade: CTCI-Press; 2004. p. 573-620.
5. Balint B, Stamatovic D, Andric Z. Stem and progenitor cell transplantation. In: Balint B, editor. Transfusion Medicine. Belgrade: CTCI-Press; 2004. p. 525-547.
6. Balint B. Stem cells - unselected or selected, unfrozen or cryopreserved: marrow repopulation capacity and plasticity potential in experimental and clinical settings. Maked Med Pregl 2004; 58 (Suppl 63): 22-24.
7. Smogorzewska EM, Weinberg KI. Treatment progress of Duchenne Muscular Dystrophy (DMD). Med Wieku Rozwoj 2004; 8(1): 25-32.
8. Yeh ETH, Zhang S, Wu HD, Kerbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003; 108: 2070-2073.
9. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297: 2256-2259.
10. Obradovic S, Rusovic S, Balint B, et al. Autologous bone marrow-derived progenitor cell transplantation for myocardial regeneration after acute infarction. Vojnosanit Pregl 2004; 61(5): 519-29.
11. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocites divide after myocardial infarction. N Engl J Med 2001; 344(23): 1750-1757.
12. Müller P, Pfeiffer P, Koglin J et al. Cardiomyocites of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation 2002; 106: 31-35.
13. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
14. Hassink RJ, de la Rivere AB, Mummery CL, et al. Transplantation of cells for cardiac repair. J Am Coll Cardiol 2003; 41(5): 771-777.
15. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9(6): 702-712.
16. Surbek DV, Holzgreve W. Stem cells from cord blood: current status and future potential. Ther Umsch 2002; 59(11): 577-582.
17. Champ Itala M, Aho H, Remes K. Reduced-intensity conditioning and blood stem cell transplantation from an HLA-identical sibling for severe aplastic anaemia: two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. Hematol J 2004; 5(5): 440-443.
18. Tabbara IA, Ingram RM. Nonmyeloablative therapy and allogeneic hematopoietic stem cell transplantation. Exp Hematol 2003; 31(7): 559-66.
19. Thomas ED, Lochte HL. Supralethal whole body irradiation and isologous marrow-transplantation in man. J Clin Invest 1959; 38: 1709-1716.
20. Mathe G, Jammet H. Transfusions et greffes de moelle osseusse homologue chez des humaines irradies a haute danse accidentellement. Rev Fr Etud Clin Biol 1959; 4: 226-238.
21. Maupin B. Development of blood disorders in persons accidentaley irradiated. Rev Int Serv Sante Armees 1960; 33: 301-312.
22. Thomas ED, Ferrebee JW. Prolonged storaged of marrow and its use in the treatment of radiation injury. Transfusion 1962; 2: 115-117.
23. Buckner CD, Stewart P, Clift RA. Treatment of blastic transformation of CGL by chemotherapy, total body irradiation and infusion of cryopreserved autolognous marrow. Exp Hematol 1978; 6: 96-100.
24. Goldman JM, Th'ng KH, Park DS, et al. Collection, cyopreservation and subsequent viability of haemopoetic stem cells intended for treatment of chronic granulocytic leukemia in blast-cell transformation. Br J Hematol 1978; 40: 185-195.
25. Lazarus HM, Pecora AL, Shea TC, et al. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome. Bone Marrow Transplant 2000; 25: 559-566.
26. Platzbecker U, Ehninger G, Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells - clinical problems and current challenges. Leuk Lymphoma 2004; 45(3): 447-453.
27. Hiett AK, Britton KA, Hague NL, et al. Comparison of hematopoietic progenitor cells in human umbilical cord blood collected from neonatal infants who are small and appropriate for gestational age. Transfusion 1995; 35: 587-591.
28. Engelfriet CP, Reesink HW. Use of cord blood progenitor cells as an alternative for bone marrow transplantation. Vox Sang 1998; 75: 156-172.
29. McCullough J, Clay M. Reasons for deferral of potential umbilical cord blood donors. Transfusion 2000; 40: 124.
30. Rogers I, Casper RF. Umbilical cord blood stem cells. Best Pract Res Clin Obstet Gynaecol 2004; 18(6): 893-908.
31. Takahashi S, Asano S. Cord blood transplantation. Gan To Kagaku Ryoho 2004; 31(3): 307-313.
32. Cohen Y, Nagler A. Umbilical cord blood transplantation - how, when and for whom? Blood Rev 2004; 18(3): 167-179.
33. Gorin NC. Collection, manipulation and freezing of haemopoetic stem cells. Clin Haematol 1986; 15: 19-48.
34. Rowley SD. Secondary processing, cryopreservation, and reinfusion of the collected product. In: Kessinger A, McMannis JD, editors. Practical considerations of apheresis in peripheral blood stem cell transplantation. Lakewood: Cobe BCT Inc; 1994. p. 53-62.
35. Rowley SD. Standards for hematopoietic progenitor cell processing. In: Brecher ME, Lasky LC, Sacher RA, Issitt LA, editors. Hematopoietic progenitor cells: processing, standards and practice. Bethesda: AABB Press; 1995. p. 183-199.
36. Balint B, Ivanovic Z, Taseski J, et al. Hematopoietic stem cells - biology and therapeutic use. Vojnosanit Pregl 1998; 55: 627-639.
37. Balint B, Ivanovic Z, Petakov M, et al. The cryopreservation protocol optimal for progenitor recovery is not optimal for preservation of MRA. Bone Marrow Transplant 1999; 23: 613-619.
38. Balint B, Bugarski D, Petakov M, et al. Quality control in haematopoietic stem cell collection and cryopreservation. In: Walterova L, Kretschmer V, Bogdanovic G, Rossi U, editors. The contribution of clinical medicine to blood safety. Procidings of the European School of Transfusion Medicine Residential Course; Belgrade (Serbia), 8-12 October 2003. Milano: ESTM; 2003. p. 91-98.
39. Balint B. Coexistent cryopreservation strategies: microprocessorrestricted vs. uncontrolled-rate freezing of the "bloodderived" progenitors/cells. Blood Banking Transf Med 2004; 2(2): 62-71.
40. Marjanović S, Balint B, Stamatović D, et al. Early treatment of extragonadal non-seminal germ cell tumor with high-doses chemotherapy support with autologous hematopoietic progenitor cell transplantation. Arch Oncology 1998; 6: 135-136.
41. Stamatovic D, Balint B, Todoric B, et al. Secondary allogeneic bone marrow transplantation in the patient with severe aplastic anemia following late graft rejection. Vojnosanit Pregl 2000; 57 (5 Suppl): 95-98.
42. Beck C, Nguyen XD, Kluter H, et al. Effect of recombinant human deoxyribonuclease on the expression of cell adhesion molecules of thawed and processed cord blood hematopoietic progenitors. Eur J Haematol 2003; 70: 136-142.
43. Tabbara IA. Allogeneic bone marrow transplantation: acute and late complications. Anticancer Res 1996; 16(2): 1019-1026.
44. Anderlini P. Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status. Cytotherapy 2002; 4(3): 241-251.
45. Tabilio A, Falzetti F, Zei T, et al. Graft engineering for allogeneic haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33(3): 274-280.
46. Arai S, Klingemann HG. Role of immunotherapy in stem cell transplantation. Int J Hematol. 2003; 77(1): 22-28.
47. Petakov M, Balint B, Bugarski D, et al. Donor leukocyte infusion - the effect of mutual reactivity of donor's and recipietnt's peripheral blood mononuclear cell on hematopoietic progenitor cells growth. Vojnosanit Pregl 2000; 57 (5 Suppl): 89-93.
48. Kolb HJ, Schmid C, Chen X, et al. Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol 2003; 110(2-3): 110-120.
49. Wilson C, Sylvanus T. Graft failure following allogeneic blood and marrow transplant: evidence-based nursing case study review. Clin J Oncol Nurs 2005; 9(2): 151-159.
50. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004; 79(3): 209-215.
51. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005; 105(11): 4200-6.
52. Martin PJ, Carpenter PA, Sanders JE, et al. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004; 79(3): 221-228.
53. Lasky LC, Ash RC, Kersey JH. Collection of pluripotential hematopoietic cells by cytapheresis. Blood 1982; 59: 822-827.
54. Balint B, Ivanovic Z. Peripheral blood stem and progenitor cell transplantation. Bull Transfus 1995; 24: 5-11.
55. Moog R. Apheresis techniques for collection of peripheral blood progenitor cells. Transfus Apheresis Sci. 2004; 31(3): 207-220.
56. Martin I, Albert A, Alcorta I, et al. Large volume leukapheresis for peripheral blood stem cell collection in children under 10 kg in weight. Bone Marrow Transplant 2003; 31(6): 517-518.
57. Sevilla J, Gonzalez-Vicent M, Madero L, et al. Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplant 2003; 31(4): 263-267.
58. Moog R, Uppenkamp M, Bock HP, et al. Harvesting of peripheral blood progenitor cells with different programmes of discontinuous flow systems. Vox Sang 1999; 76: 50-54.
59. Martin I, Albert A, Alcorta I, et al. Large volume leukapheresis for peripheral blood stem cell collection in children under 10 kg in weight. Bone Marrow Transplant 2003; 31(6): 517-518.
60. Sevilla J, Gonzalez-Vicent M, Madero L, et al. Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplant 2003; 31(4): 263-267.
61. Moncada V, Bolan C, Yau YY, et al. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43(4): 495-501.
62. Sohn SK, Kim JG, Chae YS, et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003; 18(1): 10-15.
63. Moreiras-Plaza M, Albo C, Ares C. Efficacy and safety of femoral vascular access for peripheral blood stem cell (PBSC) collection. Bone Marrow Transplant 2004; 33(3): 347-350.
64. Saif MW, Lehman SF, Cusack G, et al. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. Ann Oncol 2004; 15(9): 1366-1372.
65. Webb IJ, Eickhoff CE, Elias AD, et al. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony stimulating factor: implications for timing and yield of hematopoietic progenitor cell collections. Transfusion 1996; 36(2): 160-167.
66. Sato N, Sawada K, Takahashi TA, et al. A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. Exp Hematol 1994; 22: 973-978.
67. Lefrere F, Audat F, Hermine O, et al. The timing of granulocyte-colony- stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Transfusion 1999; 39: 561-564.
68. Lee JL, Kim SB, Lee GW, et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003; 18(1): 27-35.
69. Demirer T, Ilhan O, Ayli M, et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6(5): 384-389.
70. Balint B. Principles of intensive haemotherapy. Belgrade: MMA/MSCG-Press, 2004.
71. Kozuka T, Ikeda K, Teshima T, et al. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion 2002; 42(11): 1514-22.
72. Kurata H, Takakuwa K, Tsuneki I, et al. Circulating highly fluorescent reticulocytes to predict the adequate harvesting of peripheral blood progenitor cells in platinum-based chemotherapy. Transfus Apheresis Sci 2002; 27(3): 199-202.
73. Lesesve JF, Lenormand B, Lacombe F. The role of high fluorescent reticulocytes in monitoring the aplasia outcome and optimizing the timing of peripheral blood stem cell harvesting. J Hematother Stem Cell Res 2002; 11(6): 987-989.
74. Carral A, de la Rubia J, Martin G, et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003; 27(1): 5-12.
75. Visani G, Malagola M, Piccaluga PP, et al. Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy? Leuk Lymphoma 2004; 45(8): 1531-1538.
76. De Witte T. Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias. Int J Hematol 2000; 72(2): 151-156
77. Reiss U, Bolotin E. New approaches to hematopoietic cell transplantation in oncology. Pediatr Clin North Am 2002; 49(6): 1437-1466.
78. Saiz A, Graus F. Transplantation of haematopoietic stem cells in multiple sclerosis. Rev Neurol 2002; 35(12): 1136-1141.
79. Smogorzewska EM, Weinberg KI, Kohn DB. Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments. Med Wieku Rozwoj 2003; 7(1): 27-34.
80. Gaziev J, Lucarelli G. Stem cell transplantation and gene therapy for hemoglobinopathies. Curr Hematol Rep 2005; 4(2): 126-131.
81. Goldman JM, Horowitz MM. The international bone marrow transplant registry. J Hematol 2002; 76(Suppl 1): 393-397.
82. Sevilla J, Fernandez-Plaza S, Diaz MA, et al. Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplant 2005; 35(Suppl 1): S17-21.